LEXINGTON, Mass. , May 5, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and...
Management to host conference call today at 4:30 p.m. ET
LEXINGTON, Mass. , March 12, 2026 /PRNewswire/ --Â Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
Led by Nantahala Capital, Stonepine Capital Management, Pointillist Partners, LLC, and The Red Hook Fund, LP
LEXINGTON, Mass. , Jan. 7, 2026 /PRNewswire/ --Â Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
5 of 8 patients (62.5%) achieved Undetectable MRD (uMRD)
LEXINGTON, Mass. , Nov. 14, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...
Management to host conference call and webcast today at 4:30 p.m. ET